摘要
目的 探讨拟人参皂苷F11在大鼠体内的药物代谢产物及其过程。方法 ip拟人参皂苷F11后 ,应用TLC分析排泄物中的代谢产物 ,并利用制备薄层分离制备代谢产物 ,通过波谱解析 (MS ,1HNMR ,13CNMR ,1H 1HCOSY)确定其结构。结果 从粪便中分离鉴定了 3种代谢产物 ,分别为拟人参皂苷RT5,ocotillol和 1个新的代谢产物F 3 1,并确定其结构为 6 O α L 吡喃鼠李糖基 ( 1- 2 ) β D 吡喃葡糖基 ( 2 0S ,2 3S ,2 4R) 达玛 2 0 ( 2 4 ) 环氧 3 β ,6α,12 β,2 3 ,2 5 五醇 ( 6 O α L rhamnopyranosyl ( 1- 2 ) β D glucopyranosyl ( 2 0S ,2 3S ,2 4R) dammar 2 0 ( 2 4 ) epoxy 3 β ,6α,12 β ,2 3 ,2 5 pentanol)。但在尿液和胆汁中并未发现任何代谢产物。 结论 拟人参皂苷F11不被肝脏代谢 。
AIM To study the metabolic pathways of psuedo ginsenoside F 11 in rats. METHODS By use of the prep TLC, the metabolites were isolated. RESULTS From the feces, three metabolites, psuedo ginsenoside R T5 , ocotillol, and a new compound, F 3 1 (44) were isolated and identified by means of NMR evidence. But, such metabolites were found from neither the bile nor the urine of the rat. F 3 1 was identified as 6 O α Lrhamnopyranosyl (1-2) β D glucopyranosyl (20S,23S,24R) dammar 20(24) epoxy 3β,6α,12β,23,25 pentanol. CONCLUSION Psuedo ginsenoside F 11 can not be metabolized in the rat liver, but can be metabolized in the large intestine of the rat.
出处
《药学学报》
CAS
CSCD
北大核心
2001年第6期427-431,共5页
Acta Pharmaceutica Sinica
